Charalambos Andreadis, MD
Enriched profileClinical Professor, Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) · University of California, San Francisco (UCSF)
Charalambos Andreadis is Clinical Professor, Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) at University of California, San Francisco (UCSF). OpenAlex indexes 304 publications with 15,309 citations (h-index 43); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Charalambos, MD, is Clinical Professor, Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) at University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center. The public record shows 304 publications with 15,309 citations (h-index 43), centered on Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 15 companies.
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lymphoma Diagnosis and Treatment
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 112.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- CAR-T Long Term Follow Up (LTFU) Study
Sponsor: Novartis Pharmaceuticals
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sponsor: National Cancer Institute (NCI)
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Sponsor: University of California, San Francisco
Industry payments
Updated 27 Aug 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20254 payments$11,599openpaymentsdata.cms.gov ↗
- Genmab U.S., Inc.Program year20254 payments
- Incyte CorporationProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.6%Kinase inhibitor24.2%Calquence40%Brukinsa26%Imbruvica19%Jaypirca14%Part D<11 patientsThalidomide Analog9.9%Revlimid67%Lenalidomide33%Part D<11 patientsDermatology
22.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.6%Acyclovir100%Part D≥37 patientsAnti-infectives
15.9%Short-acting sulfonamides5.4%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor5.2%Entecavir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
74 congress contributions (2006–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
Journal of clinical oncology
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03ATP citrate lyase inhibition can suppress tumor cell growth1,098 citations2005
- 04
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/charalambos-andreadis-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/babis-andreadis-8765b614
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Charalambos-Andreadis
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Columbia University College of Physicians and Surgeons (Vagelos)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗ - MS/MSCE
Clinical Epidemiology, University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗ - Board Certified
Hematology (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗ - Board Certified
Medical Oncology (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗ - Residency
Internal Medicine, New York-Presbyterian Hospital/Columbia University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Fellowship
Hematology-Oncology, Hospital of the University of Pennsylvania
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Member
ASCO 2015 Annual Meeting Scientific Program Committee, Leukemia, Myelodysplasia, and Transplantation track (historical/dated role, not confirmed current)
2015verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Media & interviews
press, podcasts and appearances- OncLive video series
recurring contributor/interviewee on CAR T-cell therapy and lymphoma treatment topics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Gregory Marcus, MD
University of California, San Francisco (UCSF)
Eric Small, MD
University of California, San Francisco (UCSF)
Adam Boxer, MD
University of California, San Francisco (UCSF)